Artia Global Partners LP
Long book
$443.5M
Q1 2026
Positions
48
Top-10 weight
73%
concentration
Last quarter
+11.2%
SPY +14.8%
Turnover
37%
of book per quarter
Strategy in plain words
auto-generated from filingsArtia Global Partners LP is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $443.5M US long book across 48 positions.
The portfolio is concentrated: the top 10 names carry 73% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: INSMED INC, ABIVAX SA-ADR, ELI LILLY & CO, TREVI THERAPEUTICS INC, ARGENX SE - ADR.
Over the last 9 quarters its long book ran on average 2.8pp per quarter behind the S&P 500, beating the index in 2 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+1.7%
Q2 2024
-2.4%
Q3 2024
-19.5%
Q4 2024
-11.5%
Q1 2025
+5.3%
Q2 2025
+25.8%
Q3 2025
+12.2%
Q4 2025
-7.2%
Q1 2026
+11.2%
Sector allocation
Healthcare 98%
Other 2%
Long book by quarter
What does Artia Global own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| INSM INSMED INC | Healthcare | 628.7K | $102.8M | 23.2% | -7.8% |
| LLY ELI LILLY & CO | Healthcare | 38.2K | $35.2M | 7.9% | -24.3% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.0M | $24.0M | 5.4% | Held |
| AZN ASTRAZENECA PLC | Healthcare | 95.4K | $18.8M | 4.2% | New |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 503.9K | $16.1M | 3.6% | Held |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 163.0K | $13.7M | 3.1% | -20.5% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 125.0K | $12.2M | 2.7% | +20.0% |
| IONS IONIS PHARMACEUTICALS INC | Healthcare | 144.4K | $10.8M | 2.4% | Held |
| EYPT EYEPOINT INC | Healthcare | 767.1K | $9.9M | 2.2% | Held |
| DGX QUEST DIAGNOSTICS INC | Healthcare | 40.8K | $8.0M | 1.8% | Held |
| ALMS ALUMIS INC | Healthcare | 325.0K | $7.2M | 1.6% | New |
| VKTX VIKING THERAPEUTICS INC | Healthcare | 180.7K | $5.9M | 1.3% | -74.9% |
| MRK MERCK & CO. INC. | Healthcare | 46.7K | $5.6M | 1.3% | New |
| 430 TERNS PHARMACEUTICALS INC | — | 104.8K | $5.5M | 1.2% | New |
| JNJ JOHNSON & JOHNSON | Healthcare | 22.6K | $5.5M | 1.2% | New |
| SION SIONNA THERAPEUTICS INC | Healthcare | 119.7K | $4.8M | 1.1% | Held |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 96.3K | $4.7M | 1.1% | Held |
| RAPP RAPPORT THERAPEUTICS INC | Healthcare | 138.5K | $4.3M | 1.0% | Held |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 65.0K | $3.8M | 0.9% | +62.5% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 137.8K | $3.7M | 0.8% | Held |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 129.8K | $3.6M | 0.8% | Held |
| PALI PALISADE BIO INC | Healthcare | 2.0M | $3.5M | 0.8% | Held |
| BIIB BIOGEN INC | Healthcare | 18.4K | $3.4M | 0.8% | New |
| PROK PROKIDNEY CORP | Healthcare | 1.8M | $3.2M | 0.7% | -1.7% |
| ABBV ABBVIE INC | Healthcare | 14.5K | $3.2M | 0.7% | Held |
| UTHR UNITED THERAPEUTICS CORP | Healthcare | 5.0K | $3.0M | 0.7% | Held |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 38.4K | $2.8M | 0.6% | +15.0% |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 22.9K | $2.4M | 0.5% | -0.1% |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 68.5K | $2.3M | 0.5% | -87.2% |
| BTSG BRIGHTSPRING HEALTH SERVICES | Healthcare | 53.8K | $2.3M | 0.5% | +29.3% |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 70.7K | $2.1M | 0.5% | Held |
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 65.5K | $2.1M | 0.5% | New |
| CELC CELCUITY INC | Healthcare | 15.6K | $1.8M | 0.4% | +20.7% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 20.4K | $1.5M | 0.3% | Held |
| KNSA KINIKSA PHARMACEUTICALS INTE | Healthcare | 29.2K | $1.4M | 0.3% | Held |
| CYTK CYTOKINETICS INC | Healthcare | 16.3K | $1.1M | 0.2% | New |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 20.9K | $819K | 0.2% | New |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 2.5K | $805K | 0.2% | Held |
| TENX TENAX THERAPEUTICS INC | Healthcare | 42.1K | $673K | 0.2% | Held |
| KOD KODIAK SCIENCES INC | Healthcare | 17.0K | $649K | 0.1% | Held |
| NUVL NUVALENT INC-A | Healthcare | 4.9K | $502K | 0.1% | -39.5% |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 5.9K | $495K | 0.1% | New |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 29.0K | $433K | 0.1% | -30.3% |
| PEPG PEPGEN INC | Healthcare | 205.3K | $363K | 0.1% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 50 | $499.4M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 55 | $705.8M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 51 | $630.9M | SEC ↗ | |
| Q3 2025 | 13F-HR/ARESTATEMENT | Nov 14, 2025 | 51 | $630.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 37 | $415.6M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 38 | $395.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 37 | $279.8M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 45 | $366.9M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 46 | $517.3M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 49 | $497.5M | canonical | SEC ↗ |